XENE Insider Trading Activity and SEC Form 4 Filings
XENE insider trading summary
Over the past 12 months, insiders at Xenon Pharmaceuticals Inc. (XENE) reported 24 sales worth $21.5M by 6 insiders and 2 open-market purchases worth $1.7M by 2 insiders on SEC Form 4. Net insider selling was $19.8M.
Latest XENE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Thomas Patrick Kelly | Chief Financial Officer | Buy | $560K (15,000 @ $37.32) |
| Sep 30, 2026 | Ian Mortimer | President & CEO | Buy | $1.1M (30,000 @ $37.38) |
| Aug 28, 2026 | Christopher John Kenney | Chief Medical Officer | Sell | $43K (700 @ $60.98) |
| Aug 28, 2026 | Christopher John Kenney | Chief Medical Officer | Sell | $383K (6,368 @ $60.17) |
| Aug 11, 2026 | Steven Gannon | Insider | Sell | $641K (10,000 @ $64.06) |
| Jun 5, 2026 | Gillian Cannon | Insider | Sell | $63K (1,190 @ $53.14) |
| Jun 5, 2026 | Gary Patou | Insider | Sell | $70K (1,322 @ $53.14) |
| Mar 13, 2026 | Christopher John Kenney | Chief Medical Officer | Sell | $78K (1,410 @ $55.23) |
| Mar 10, 2026 | Christopher John Kenney | Chief Medical Officer | Sell | $167K (2,771 @ $60.11) |
| Mar 10, 2026 | Ian Mortimer | President & CEO | Sell | $677K (11,269 @ $60.11) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.